Search Results - Clinical+Specialty+%3e+Oncology

12 Results

Sort By:

Pharmacological EZH2 inhibition enhances cancer cell sensitivity to genotoxic insults through suppressing DNA damage repair

HSC-1535 Pharmacological EZH2 inhibition enhances cancer cell sensitivity to genotoxic insults through suppressing DNA damage repairKexin Xu: Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.Myles Brown: Center for Functional Cancer Epigenetics and Department of Medical Oncology,...

Published: 7/29/2022 | Inventor(s): Kexin Xu, Myles Brown, Chen-Hao Chen, Xiaole Shirley Liu, CPRIT

Keywords(s):

Category(s): Clinical Specialty > Oncology, Clinical Specialty > Radiology, Diagnostics > Assay, Life Sciences Research Tools > Biomarkers

CsA treatment for BRCA1 mutant cancers

I have demonstrated that BRCA1-mutant triple-negative breast cancer (TNBC) cells are highly sensitive to cyclosporine (CsA) and non-immunosuppressive CsA-derivatives (NIM811 or Alisporivir). To determine whether CsA would also be effective in treating BRCA1-mutant TNBC cells in vivo, I set up a pilot study using a preclinical xenograft model to investigate...

Published: 10/5/2021 | Inventor(s): Kimi Yuk-Ling Kong

Keywords(s):

Category(s): Clinical Specialty > Oncology, Clinical Specialty > Women's Health, Clinical Specialty > Endocrinology, Life Sciences Research Tools > Drug Screening, Therapeutics > Small Molecule

A new approach for treatment of liver cancers

The early stage of hepatocellular carinoma (HCC) tumors (<5cm) can either be excised surgically, or removed byablation therapy, but treatment of advanced stage HCC remain challegning. Since, HCC and other liver cancersare diagnosed at advanced stage, their surgical excision is not feasible. The existing front- and second-linetherapies for advanced...

Published: 9/14/2023 | Inventor(s): Yogesh Gupta

Keywords(s):

Category(s): Clinical Specialty > Oncology, Life Sciences Research Tools > Drug Screening, Therapeutics > Small Molecule, Clinical Specialty > Hepatology

MicroRNA mimics as potential differentiation agents for treating neuroblastoma

Neuroblastoma,themostcommonextracranialsolidtumorofchildhood,arisesfromneuralcrestcellprecursorsthatfailtodifferentiate.Inducingcelldifferentiationisanimportanttherapeuticstrategyforneuroblastoma.Wedevelopedadirectfunctionalhigh-‐contentscreentoidentifydifferentiation-‐inducingmicroRNAs,inordertodevelopmicroRNA-‐baseddifferentiationtherapyforneuroblastoma.WediscoverednovelmicroRNAs,andmorestrikingly,threemicroRNAseedfamiliesthatinduceneuroblastomacelldifferentiation.Inaddition,weshowedthatmicroRNAseedfamilieswereoverrepresentedintheidentifiedgroupoffourteendifferentiation-‐inducingmicroRNAs,suggestingthatmicroRNAseedfamiliesarefunctionallymoreimportantinneuroblastomadifferentiationthanmicroRNAswithuniquesequences.Wefurtherinvestigatedthedifferentiation-‐inducingfunctionofthemicroRNA-‐506-‐3p/microRNA-‐124-‐3pseedfamily,whichwasthemostpotentinducerofdifferentiation.Weshowedthatthedifferentiation-‐inducingfunctionofmicroRNA-‐506-‐3p/microRNA-‐124-‐3pismediated,atleastpartially,bydown-‐regulatingexpressionoftheirtargetsCDK4andSTAT3.WefurthershowedthatexpressionofmiR-‐506-‐3p,butnotmiR-‐124-‐3p,isdramaticallyup...

Published: 9/14/2023 | Inventor(s): Liqin Du, Alexander Pertsemlidis

Keywords(s):

Category(s): Clinical Specialty > Oncology, Clinical Specialty > Neurology, Therapeutics > miRNA

Method of targeting liposomes to bone marrow

UT Health San Antonio and Waseda University in Shinjuku, Japan have collaboratively developed a drug delivery system capable of delivering a cargo preferentially to bone marrow. This drug delivery system shows promise for therapeutic and diagnostic applications for which the cells of the bone marrow play an important role. Background:Targeted anti-cancer...

Published: 4/26/2022 | Inventor(s): William Phillips, Beth Goins, Keitaro Sou, Shinji Takeoka, Eishun Tsuchida

Keywords(s): Biologics, Drugs

Category(s): Clinical Specialty > Oncology, Therapeutics > Biologics, Therapeutics > Other

PARP-1 Inhibitor Nanoparticle and Treatment Method for Ewing Sarcoma

A novel nanoparticle formulation of an existing PARP-1 inhibitor and an associated administration regimen has been developed for the treatment of Ewing Sarcoma. This technology allows the therapeutic treatment to be targeted to the tumors, resulting in reduced required doses and system toxicity.Background:Ewing Sarcoma is rare cancer of the bone that...

Published: 12/7/2023 | Inventor(s): Raushan Kurmasheva, Kytai Nguyen

Keywords(s):

Category(s): Clinical Specialty > Orphan Diseases, Clinical Specialty > Orthopedics, Therapeutics > Nanoparticles, Clinical Specialty > Oncology, Therapeutics > Small Molecule

Micro-RNA Therapy for High-Risk Pediatric Brain Cancer

A MicroRNA therapy has been developed for the purpose of increasing the chemo- and radio-sensitivity of tumor cells in Medulloblastoma. The invention would allow for lower dosages of radiation and chemotherapy by working synergistically with these therapies, thus reducing adverse side effects. It may also lead to more complete eradication of the tumor...

Published: 10/17/2023 | Inventor(s): Manjeet Rao, Nourhan Abdelfattah

Keywords(s):

Category(s): Therapeutics > Biologics, Therapeutics > Nucleic Acids, Clinical Specialty > Neurology, Clinical Specialty > Oncology, Clinical Specialty > Pediatrics

Novel Capsazepine Analogs to Treat Cancer

Novel compounds have been developed based upon the capsazepine pharmacophore that are effective in halting tumor cell proliferation in vitro and in vivo. Capsazepine is a known, off-patent, analog of Capsaicin that has been proposed and studied as a TRPV1 antagonist for treatment of pain. Although Capsazepine has been proposed for alleviation of pain,...

Published: 3/15/2024 | Inventor(s): Cara Gonzales, Stanton McHardy

Keywords(s):

Category(s): Clinical Specialty > Oncology, Therapeutics > Small Molecule

Intravenous Tramadol for Treatment of anti-NMDA Encephalitis

The invention is a combinatorial therapy used to enhance the efficacy of plasma exchange (PLEX) in treating patients with anti-NMDAR encephalitis. This treatment regimen would treat both the psychiatric and immunological manifestations of this disorder and substantially lower the patients’ recovery periods. Background:Anti-NMDAR encephalitis is...

Published: 12/7/2023 | Inventor(s): Ali Seifi

Keywords(s):

Category(s): Therapeutics > Small Molecule, Clinical Specialty > Neurology, Clinical Specialty > Oncology, Clinical Specialty > Immunology

Allosteric Proteasome Inhibitors for Treatment of Cancer

UT Health San Antonio scientists have discovered novel small-molecule compounds that have allosteric signaling activity to modulate proteasome catalytic activity. The allosteric proteasome inhibitors can be used alone or in combination with existing competitive proteasome inhibitors for the treatment of cancer. Studies of combination treatment demonstrate...

Published: 4/1/2024 | Inventor(s): Pawel Osmulski, Maria Gaczynska

Keywords(s):

Category(s): Therapeutics > Small Molecule, Clinical Specialty > Oncology

1 2